Trial reportBlood2012
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Trial report in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance
A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance
A Phase III Study for Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 (TT2, UARK 98-026): Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Melphalan, and Dexamethasone
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2015Guideline
- European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Haematologica · 2014Guideline
- Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.International journal of clinical and experimental pathology · 2014Pooled it
- Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.Journal of hematology & oncology · 2016Trial
- New cancers after autotransplantations for multiple myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Trial
- Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.Blood · 2013Trial
- Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.Blood advances · 2025Article
- High WEE1 expression is independently linked to poor survival in multiple myeloma.Blood cancer journal · 2025Article
- High WEE1 expression is independently linked to poor survival in multiple myeloma.bioRxiv : the preprint server for biology · 2024Article
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.Cancers · 2024Article
- Article
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial.EClinicalMedicine · 2023Article
- Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance.Journal of personalized medicine · 2023Article
- Autophagy-related genes affect the survival of multiple myeloma patients depending on chromosomal abnormality.Asian biomedicine : research, reviews and news · 2022Article
- Exploiting gene dependency to inform drug development for multiple myeloma.Scientific reports · 2022Article
- Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.Frontiers in pharmacology · 2022Article
- Second primary malignancies in multiple myeloma: A review.Blood reviews · 2021Review
- Second malignancies in multiple myeloma; emerging patterns and future directions.Best practice & research. Clinical haematology · 2020Review
- Article
- Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.Leukemia · 2019Article
Corrections and comments
- Commented on bySecond to none.2012
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
Thalidomide and lenalidomide constitute an important part of effective myeloma therapy. Recent data from the Intergroup Francophone du Myélome, Cancer and Leukemia Group B, and Gruppo Italiano Malattie Ematologiche dell Adulto MM-015 trials suggest that lenalidomide maintenance therapy is associated with a higher incidence of second primary malignancies (SPMs), including both hematologic and solid malignancies. In the present study, we analyzed data from the Total Therapy 2 (TT2) trial, along with the 2 Total Therapy 3 (TT3) trials. TT2 patients were assigned randomly to either a control group (no thalidomide) or to the experimental group (thalidomide during induction, between transplantations, and during consolidation and maintenance). The 2 TT3 trials used thalidomide and bortezomib during induction, before and in consolidation after tandem melphalan-based transplantation; TT3A applied VTD (bortezomib, thalidomide, dexamethasone) in the first year of maintenance and TD for 2 more years, whereas TT3B used VRD (bortezomib, lenalidomide, dexamethasone) maintenance for 3 years. The cumulative incidence of SPMs did not differ significantly among the TT trial components when measured from enrollment (P = .78) or from initiation of maintenance (P = .82). However, a pairwise comparison of the TT2 arms suggested a lower incidence of hematologic SPMs in the thalidomide maintenance arm (hazard ratio = 0.38; P = .09). These trials are registered at www.clinicaltrials.gov as NCT00573391 (TT2), NCT00081939 (TT3A), and NCT00572169 (TT3B).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.